Autonomic Dysfunction in Resistant Hypertension (RH)
|ClinicalTrials.gov Identifier: NCT01833429|
Recruitment Status : Completed
First Posted : April 16, 2013
Last Update Posted : April 16, 2013
|Condition or disease|
|Hypertension, Resistant to Conventional Therapy|
All patients were submitted to office blood pressure measurement, Ambulatory blood pressure monitoring and 24-hour Holter monitoring.
Baseline blood samples for the measurement of glycemia (mg/dL), total cholesterol (mg/dL), LDL cholesterol (mg/dL), triglycerides (mg/dL), creatinine (mg/dL), serum uric acid, serum sodium, serum potassium, plasma aldosterone concentration (PAC) and plasma renin activity (PRA) were collected at 08:00 after overnight fasting.
|Study Type :||Observational [Patient Registry]|
|Actual Enrollment :||44 participants|
|Target Follow-Up Duration:||10 Months|
|Official Title:||Circadian Autonomic Disturbances in Resistant Hypertension With and Without White-coat Phenomenon|
|Study Start Date :||September 2011|
|Primary Completion Date :||November 2012|
|Study Completion Date :||December 2012|
The current definition of resistant hypertension (RH) includes both patients whose blood pressure (BP) is uncontrolled on three or more medications and those whose BP is controlled when using four or more antihypertensive medications
- evaluation of the autonomic function in resistant hypertensive patients [ Time Frame: 10 months ]
The autonomic nervous system can be assessed by the heart rate variability. Variations in heart rate variability are normally observed in association with diurnal rhythms and blood pressure changes. The heart rate variability parameters are different in many studies, although the consensus is that lower values of the indices of vagal as well as high indices of sympathetic functions are associated prospectively with death and disability.
In humans, the disturbances of the circadian rhythms of heart rate variability and blood pressure have been intensively studied, mainly due to the increased cardiovascular death reported during the morning hours
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01833429
|Cardiovascular Pharmacology Laboratory|
|Campinas, Sao Paulo, Brazil, 13083-888|